SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $67,475 | -27.9% | 4,647 | +4.0% | 0.00% | – |
| Q2 2023 | $93,557 | -2.5% | 4,470 | -1.6% | 0.00% | – |
| Q1 2023 | $95,949 | -12.9% | 4,543 | +4.9% | 0.00% | – |
| Q4 2022 | $110,199 | +6.0% | 4,330 | 0.0% | 0.00% | – |
| Q3 2022 | $104,000 | +25.3% | 4,330 | 0.0% | 0.00% | – |
| Q2 2022 | $83,000 | +10.7% | 4,330 | 0.0% | 0.00% | – |
| Q1 2022 | $75,000 | -21.1% | 4,330 | 0.0% | 0.00% | – |
| Q4 2021 | $95,000 | +14.5% | 4,330 | 0.0% | 0.00% | – |
| Q3 2021 | $83,000 | +12.2% | 4,330 | 0.0% | 0.00% | – |
| Q2 2021 | $74,000 | -23.7% | 4,330 | 0.0% | 0.00% | – |
| Q1 2021 | $97,000 | +1.0% | 4,330 | 0.0% | 0.00% | – |
| Q4 2020 | $96,000 | +50.0% | 4,330 | 0.0% | 0.00% | – |
| Q3 2020 | $64,000 | 0.0% | 4,330 | 0.0% | 0.00% | – |
| Q2 2020 | $64,000 | +33.3% | 4,330 | 0.0% | 0.00% | – |
| Q1 2020 | $48,000 | +26.3% | 4,330 | 0.0% | 0.00% | – |
| Q4 2019 | $38,000 | +18.8% | 4,330 | 0.0% | 0.00% | – |
| Q3 2019 | $32,000 | -20.0% | 4,330 | 0.0% | 0.00% | – |
| Q2 2019 | $40,000 | +73.9% | 4,330 | 0.0% | 0.00% | – |
| Q1 2019 | $23,000 | +21.1% | 4,330 | 0.0% | 0.00% | – |
| Q4 2018 | $19,000 | -45.7% | 4,330 | 0.0% | 0.00% | – |
| Q3 2018 | $35,000 | +16.7% | 4,330 | 0.0% | 0.00% | – |
| Q2 2018 | $30,000 | -51.6% | 4,330 | 0.0% | 0.00% | – |
| Q1 2018 | $62,000 | +63.2% | 4,330 | 0.0% | 0.00% | – |
| Q4 2017 | $38,000 | -25.5% | 4,330 | 0.0% | 0.00% | – |
| Q3 2017 | $51,000 | – | 4,330 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |